Bristol-Myers Squibb (BMY) Tops Q1 EPS by 9c; Boosts FY16 Outlook

Bristol-Myers Squibb (NYSE: BMY) reported Q1 EPS of $0.74, $0.09 better than the analyst estimate of $0.65. Revenue for the quarter came in at $4.39 billion versus the consensus estimate of $4.19 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2016 EPS of $2.50-$2.60, versus the consensus of $2.40.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c